Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06977854 · ClinicalTrials.gov registry record

The Objective of This Study Was to Compare and Quantify the Bioavailability of Citrulline Byproducts in Blood Samples and in Urine Samples After a Single Dose of the Assigned Dietary Supplement. The Treatment Arms Containing the Following Molecules: Citrulline HCL and L-Citrulline,

A clinical trial, sponsored by Vireo Systems.

Completed
Registry status
32
Enrollment target

NCT06977854: Completed study, sponsored by Vireo Systems.

NCT06977854 is a clinical trial that has completed, run by Vireo Systems. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06977854 has completed, sponsored by Vireo Systems.

COMPLETED
Registry status
32 participants
Enrollment target

Study Summary

Citrulline dietary supplements are of interest for improving cardiovascular and exercise performance. The health benefits of citrulline are attributable to its ability to increase arginine levels in the body through the intestinal-renal arginine conversion pathway. From a dietary supplementation standpoint, citrulline offers advantages over arginine due to its reduced first-pass metabolism and ready conversion to arginine within the body. While L-citrulline is the most widely used citrulline dietary supplement, additional salt forms such as citrulline maleate and citrulline HCl may provide improvements in the delivery of arginine to the body. The present study compared the single-dose pharmacokinetics of L-citrulline and citrulline HCl formulations in healthy human subjects. A total of 17 subjects were randomly assigned to groups receiving either 6 g of L-citrulline, 6 g of citrulline HCl or 2 g of citrulline HCl. The resulting increases in citrulline and arginine in plasma and urine samples were determined using liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM/MS). All citrulline dietary supplements examined produced time-dependent increases in plasma citrulline and arginine. Both maximal plasma concentration (Cmax) and area under the plasma vs time curve (AUC) for citrulline were modestly reduced in the 6 g citrulline HCl treatment group, the resulting arginine Cmax and AUCs were similar for both L-citrulline and citrulline HCl at the 6 g dose. While the 2 g dose of citrulline HCl had reduced Cmax and AUC values compared to 6 g doses, the time to reach peak levels of arginine were significantly shorter. Furthermore, examination of the relative arginine bioavailability achieved with the 6 g and 2 g citrulline HCl compared to the 6 g L-citrulline was approximately 120% and 215%, respectively, consistent with an improved citrulline to arginine conversion efficiency with the citrulline HCl formulations.

Primary Outcome

Measured blood plasma arginine levels at various time points.

Interventions

  • OTHER Removal from study. In case of adverse event, subject treated for the AE.
  • OTHER removal from study

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2024-07-13
Est. Completion 2024-07-27
Vireo Systems

3 total trials

What the finished NCT06977854 record still lists

NCT06977854 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 32 participants, a relatively small participant target.

The record links to 0 conditions, and to 2 interventions - of which Removal from study. In case of adverse event, subject treated for the AE. is the first listed.

NCT06977854 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06977854 about?

NCT06977854 is a clinical study titled "The Objective of This Study Was to Compare and Quantify the Bioavailability of Citrulline Byproducts in Blood Samples and in Urine Samples After a Single Dose of the Assigned Dietary Supplement. The Treatment Arms Containing the Following Molecules: Citrulline HCL and L-Citrulline,". Citrulline dietary supplements are of interest for improving cardiovascular and exercise performance. The health benefits of citrulline are attributable to its ability to increase arginine levels in the body through the intestinal-renal arginine conversion pathway. From a dietary supplementation sta...

What is the current status of trial NCT06977854?

This trial is currently completed. The enrollment target is 32 participants. The study started on 2024-07-13. Estimated completion is 2024-07-27.

What interventions are being tested in trial NCT06977854?

The interventions under investigation include: Removal from study. In case of adverse event, subject treated for the AE. (OTHER), removal from study (OTHER).

Who is sponsoring clinical trial NCT06977854?

This trial is sponsored by Vireo Systems, which has 3 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06977854, the US trial registry maintained by the National Library of Medicine. NCT06977854 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.